Atrium integrates Trophic Canada
This article was originally published in The Tan Sheet
Executive Summary
With its integration of Trophic Canada completed in the second quarter, Atrium Innovations reports 17.3 percent revenue growth to $85.2 million. Atrium bought Trophic for $11 million to bolster its Canadian operations through the Trophic and Wild Rose supplement brands (1"The Tan Sheet" April 12, 2010, In Brief). The 2009 Garden of Life acquisition also boosted sales and Atrium CEO Pierre Fitzgibbon said in an Aug. 12 release the Quebec City firm still is assessing "multiple opportunities for acquisitions." Atrium's net earnings grew 11.4 percent to $12.5 million in the three months ended June 30, and diluted net earnings per share increased to 38 cents from 34 cents
You may also be interested in...
Interview: Health & Wellness Investment Bank PCGA Prioritizes Supplement Innovation, Quality
Investment capital has followed the flood of consumer interest in the natural health and wellness market. Partnership Capital Growth Advisors was founded as an investment bank and financial advisor in 2005 to focus precisely on the "healthy, active and sustainable living" segment.
Atrium Innovations acquires Trophic Canada
Atrium Innovations' $11 million acquisition of the vitamin, mineral and supplement maker and distributor Trophic Canada gives the marketer "a stronger and complementary foothold" in the Canadian market. Trophic's two brands, Trophic and Wild Rose, include 150 products and sell approximately $7.5 million annually, primarily in specialized health food stores, according to Atrium's March 18 release. Atrium entered health food stores last September with the acquisition of Garden of Life (1"The Tan Sheet" Sept. 22, 2009). Before that it acquired enzyme manufacturer Enyzm-Arzeimittel-Berlin (2"The Tan Sheet" May 25, 2009, In Brief)
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.